The Center for Biosimilars® recaps the top news for the week of February 25, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 25.
Number 5: New psoriasis treatment guidelines say that anti—tumor necrosis factor biosimilars can be considered therapeutically interchangeable with their reference products.
Number 4: A newly published paper looks ahead to the potential for—and challenges related to—biosimilars of products like gene and cell therapies.
Number 3: As part of its investigation into drug pricing, the Senate Finance Committee is launching a bipartisan probe into insulin prices.
Number 2: Sandoz has filed suit against Amgen, asking the court for a declaratory judgment of patent noninfringement and invalidity.
Number 1: A judge has directed Boehringer Ingelheim to disclose its launch plans for its biosimilar adalimumab as part of a long-running patent dispute with AbbVie.
Finally, last week, our e-newsletter asked which stakeholder group you think has the most influence in combatting misinformation on biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.